Management of nonalcoholic fatty liver disease in children
Jean P. Molleston – 25 September 2012 – Watch a video presentation of this article
Natural history of nonalcoholic fatty liver disease
Rohini Mehta, Zobair M. Younossi – 25 September 2012 – Watch a video presentation of this article
Histological assessment of nonalcoholic fatty liver disease in adults and children
Elizabeth M. Brunt – 25 September 2012 – Watch a video presentation of this article
Nonalcoholic fatty liver disease: Indications for liver biopsy and noninvasive biomarkers
Mazen Noureddin, Rohit Loomba – 25 September 2012 – Watch a video presentation of this article
Liver transplantation and nonalcoholic fatty liver disease
Kymberly D. Watt – 25 September 2012 – Watch a video presentation of this article
Nonalcoholic fatty liver disease: Indications for liver biopsy and noninvasive biomarkers
Mazen Noureddin, Rohit Loomba – 25 September 2012 – Watch a video presentation of this article
Nonalcoholic fatty liver disease: Definitions, risk factors, and workup
Puneet Puri, Arun J. Sanyal – 25 September 2012 – Watch a video presentation of this article
Pediatric nonalcoholic fatty liver disease: Prevalence, diagnosis, risk factors, and management
Stavra A. Xanthakos, Rohit Kohli – 25 September 2012 – Watch a video presentation of this article
Histological assessment of nonalcoholic fatty liver disease in adults and children
Elizabeth M. Brunt – 25 September 2012 – Watch a video presentation of this article
Efficacy of the retreatment of hepatitis C virus infections after liver transplantation: Role of an aggressive approach
Marina Berenguer, Bruno Roche, Victoria Aguilera, Jean‐Charles Duclos‐Vallée, Laia Navarro, Angel Rubín, Jose‐Antonio Pons, Manuel de la Mata, Martín Prieto, Didier Samuel – 25 September 2012 – A sustained virological response (SVR) is achieved by 30% of naive liver transplantation (LT) recipients treated with pegylated interferon (PEG‐IFN) and ribavirin (RBV). Almost no data are available about retreatment. The aim of this study was to assess the efficacy, tolerability, and SVR predictors of retreatment.